NANOG and neoplasm: It has been demonstrated that SPOP acts as a tumor suppressor in prostate cancer by primarily targeting the pluripotency-maintaining transcription factor Nanog for polyubiquitination and subsequent degradation, thereby inhibiting prostate CSC traits.